pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PTGXProtagonist Therapeutics, Inc

$PTGX150.00+2.83%
Newark, CA, USupdated 5h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
pre_registration: 1
1pre_registration
pre_registration
rusfertide acetate
Polycythemia Vera

📅 Upcoming

Nov 5, 2026
earnings
$PTGX150.00+2.83%
in 3mo
Protagonist Therapeutics, Inc earnings
Protagonist Therapeutics, Inc
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.completedn=146
  • phase2Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitisterminatedn=98
  • phase2PTG-300 in Subjects With Hereditary Hemochromatosiscompletedn=16
  • phase3A Phase 3 Study of Rusfertide in Patients With Polycythemia Veraactive not recruitingn=293
  • phase2Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)completedn=70
  • phase3Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Veraactive not recruitingn=46
  • phase2PTG-300 in Patients With Polycythemia Vera and Elevated Hematocritcompletedn=20

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 20, 26SELLAli Asif· Chief Financial Officer1,750 sh @ $105.47−$185K↗
  • Mar 26, 26SELLAli Asif· Chief Financial Officer24,765 sh @ $104.24−$2.58M↗
  • Mar 26, 26SELLSELICK HAROLD E· 24,000 sh @ $105.00−$2.52M↗
  • Mar 26, 26SELLMOLINA ARTURO MD· Chief Medical Officer15,000 sh @ $104.79−$1.57M↗
  • Mar 25, 26SELLPATEL DINESH V PH D· President and CEO54,641 sh @ $101.00−$5.52M↗
  • Mar 24, 26SELLPATEL DINESH V PH D· President and CEO59 sh @ $101.00−$6K↗
  • Feb 17, 26SELLWilliams Lewis T· 18,000 sh @ $82.42−$1.48M↗
routine RSU / option mechanics (6)
  • Apr 23, 26giftPATEL DINESH V PH D · President and CEO1,460 sh
  • Mar 26, 26option exerciseAli Asif · Chief Financial Officer19,500 sh
  • Mar 26, 26option exerciseSELICK HAROLD E · 24,000 sh
  • Mar 26, 26option exerciseMOLINA ARTURO MD · Chief Medical Officer15,000 sh
  • Mar 26, 26option exerciseAli Asif · Chief Financial Officer5,265 sh
  • Mar 26, 26option exerciseAli Asif · Chief Financial Officer19,500 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
7 open roles at Protagonist Therapeutics, Inc →

Where Protagonist Therapeutics, Inc is staffing up — a leading indicator of pipeline and commercial priorities.

departmentR&D / Discovery 7

News

no news has mentioned this company yet
identifiers
ticker
$PTGX
SEC CIK
0001377121
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 28m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?